Table 3

Positivity for ER, PR, p53, p21, p63, and KI-67 in HUT areas of reduction aesthetic mammaplasty specimens (HUT-ARM), HUT of mammaplasty contralateral to breast cancer (HUT-MCC); HUT adjacent to invasive mammary carcinoma (HUT-IMC), and in invasive mammary carcinoma (IMC)

Antibody

HUT-ARM n (%)

HUT-MCC n (%)

HUT-IMC n (%)

IMC n (%)


RE

33 (97.1)

13 (86.7)

32 (94.1)

18 (52.9)

RP

34 (100)

12 (80,0)

33 (97.1)

18 (52.9)

p53

0 (0)

0 (0)

0 (0)

19 (55.9)

p21

0 (0)

0 (0)

N*- 2 (5.9)

N*- 19 (55.9)

C*- 6 (17.6)

C*- 8 (23.5)

p63

34 (100)

15 (100)

34 (100)

3 (8.8)

Ki-67 **

L- 20 (58.8)

L- 4 (26.7)

L- 22 (64.7)

L- 9 (26.5)

I- 2 (5.9)

I- 2 (13.3)

I- 5 (14.7)

I- 17 (50)

H- 8 (23.5)


* Localization of p21 staining: N- nuclear, C- cytoplasmatic

** KI-67 expressed as: L-low, I-intermediate, and H-high proliferative index

Tafuri et al. BMC Cell Biology 2006 7:29   doi:10.1186/1471-2121-7-29

Open Data